1.     Meyer B. FDA "Black Box" Labeling. Ann Emerg Med. 2003 Apr; 41(4):55960

2.     Lischke V, et al. Droperidol causes a dose-dependent prolongation of the QT interval. Anesth Analg. 1994; 79:983-986

3.     Guy JM, et al. Torsades de pointes et allongement de la duree de l'intervalle QT apres injection de droperidol. An de Cardiologie et d'Angeiolie. 1991; 40:541-545

4.     Reilly et al. QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients. Lancet 2000; 355:1048--52

5.     Lawrence & Nasraway, Pharmacotherapy 1997; 17(3): 531-7

6.     Frye et al. Continuous droperidol infusion for management of agitated delirium in an intensive care unit. Psychosomatics 1995; 36:301-5

7.     Drolet B et al. Droperidol lengthens cardiac repolarization due to block of the rapid component of the delayed rectifier potassium current. J Cardiovas Electrophys 1999; 10(12):1597--604

8.     Michalets et a. Torsade de pointes resulting from the addition of droperidol to an existing cytochrome P450 drug interaction. Ann Pharmacother 1998; 32(7-8):761-5

9.     Faigel et al. Torsade de pointes complicating the treatment of bleeding esophageal varices: association with neuroleptics, vasopressin, and electrolyte imbalance. Am J Gastroenterol 1995; 90(5):822-4

10. Roden D. Acquired long QT syndromes and the risk of proarrhythmia. J Cardiovasc Electrophys 2000; 11:938-40

11. Fenichel RR. Development of drugs that alter ventricular repolarization. Am J Ther 2002; 9(2):127-39

12. Malik M and Camm AJ. Evaluation of drug-induced QT interval prolongation. Drug Safety 2001; 24(5):323-351

13. Curran ME et al. Molecular mechanism of a serious adverse drug reaction: drug induced cardiac arrhythmias. Pharm Disc Development, 2002/03

14. Keating MT and Sanguinetti MC. Molecular and cellular mechanisms of cardiac arrhythmias. Cell 2001; 104:569-80